Companies · VRTX
Vertex Pharmaceuticals
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 3, 2026
Vertex acquires Crinetics for $10B, adding PALSONIFY and atumelnant while povetacicept BLA targets November 30 FDA decision
Vertex's Q3 2026 10-Q is defined by two simultaneous inflection points: the $9.6 billion closing of the Crinetics acquisition on September 1, bringing a commercial acromegaly asset (PALSONIFY) and a Phase 3 rare endocrine pipeline candidate (atumelnant) onto the balance sheet, and the FDA's priority review of povetacicept with a PDUFA date of November 30, 2026. Net product revenues reached $3.44 billion in Q3, up 12% from Q3 2025, driven by ALYFTREK's 186% growth partially offsetting TRIKAFTA/KAFTRIO's 8% decline as the portfolio transitions to the next-generation CF regimen. The Crinetics integration introduces a new risk factor this quarter — integration failure risk on a $10 billion deal — while simultaneously expanding Vertex's commercial and pipeline footprint into rare endocrine diseases for the first time.
Tone: bullishRevenue
$12B
VRTX 10-K · FY 2025
Employees
6,400
Revenue FY2024
$11B
Founded
1989
Profile
VRTX 10-K Item 1 · Feb 13, 2026Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases in specialty markets. It has approved products for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain, and is advancing a mid- and late-stage pipeline across kidney disease, neuropathic pain, and type 1 diabetes. The company operates in a single pharmaceutical segment and commercializes its medicines globally.
Read filing description ↓ Collapse description ↑
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis ('CF'), sickle cell disease ('SCD'), transfusion dependent beta thalassemia ('TDT'), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas. Our mid- and late-stage clinical pipeline includes programs across a range of modalities in additional serious diseases, including IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, autosomal dominant polycystic kidney disease, and myotonic dystrophy type 1. Our core strategy is to discover, develop, and commercialize innovative medicines by combining transformative advances in the understanding of human disease and the science of therapeutics, to dramatically advance human health. We focus on validated targets that address causal human biology, predictive lab assays and clinical biomarkers, rapid paths to registration and approval, and product candidates that hold the potential for transformative patient benefit. Our approach includes advancing multiple compounds or therapies from each program into early clinical trials to obtain patient data that can inform selection of the most promising therapies for later stage development as well as inform our ongoing discovery and development efforts. We aim to serially innovate in our disease areas of interest and follow our first-in-class therapies with potential best-in-class candidates. We maintain a strong financial profile as we continue to invest in our serial innovation strategy, launch new products, advance our diverse pipeline, and expand geographically.
Primary products
- ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor)
- TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
- SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor)
- ORKAMBI (lumacaftor/ivacaftor)
- KALYDECO (ivacaftor)
- CASGEVY (exagamglogene autotemcel)
Business segments
End markets
Geographies
“We believe our long-term competitive success depends on discovering and developing or acquiring transformative medicines for people with serious diseases and continuously improving the productivity of our operations in a highly competitive environment.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenues increased to $12.0 billion in 2025 from $11.0 billion in 2024, primarily due to continued strong demand for TRIKAFTA/KAFTRIO and contributions from launches of ALYFTREK, JOURNAVX, and CASGEVY.
The rest of VRTX is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.